(VIANEWS) – UCB (UCB.BR) is among this list of stock assets with the highest dividend rate and return on equity on the Biotechnology industry.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| UCB (UCB.BR) | €82.58 | 1.62% | 3.7% |
| TUBIZE-FIN (TUB.BR) | €72.60 | 1.19% | 4.93% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. UCB (UCB.BR)
1.62% Forward Dividend Yield and 3.7% Return On Equity
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, China, Italy, the United Kingdom, Ireland, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Earnings Per Share
As for profitability, UCB has a trailing twelve months EPS of €1.7.
PE Ratio
UCB has a trailing twelve months price to earnings ratio of 48.58. Meaning, the purchaser of the share is investing €48.58 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.7%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, UCB’s stock is considered to be overbought (>=80).
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Apr 28, 2023, the estimated forward annual dividend rate is 1.33 and the estimated forward annual dividend yield is 1.62%.
Yearly Top and Bottom Value
UCB’s stock is valued at €82.58 at 21:40 EST, below its 52-week high of €88.80 and way above its 52-week low of €65.40.
More news about UCB.
2. TUBIZE-FIN (TUB.BR)
1.19% Forward Dividend Yield and 4.93% Return On Equity
Financière de Tubize SA operates as a mono holding company whose sole investment is a stake in UCB which is a biopharma company in Belgium. The company is based in Brussels, Belgium.
Earnings Per Share
As for profitability, TUBIZE-FIN has a trailing twelve months EPS of €2.
PE Ratio
TUBIZE-FIN has a trailing twelve months price to earnings ratio of 36.3. Meaning, the purchaser of the share is investing €36.3 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.93%.
Moving Average
TUBIZE-FIN’s value is higher than its 50-day moving average of €69.76 and above its 200-day moving average of €70.99.
Volatility
TUBIZE-FIN’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.39%, a positive 0.08%, and a positive 1.28%.
TUBIZE-FIN’s highest amplitude of average volatility was 1.39% (last week), 1.03% (last month), and 1.28% (last quarter).
More news about TUBIZE-FIN.
